Floatz logo

Gabapentin

Nervous System Cancer

Explore 1 assets in Nervous System Cancer →
Floatz Rating
D30/100
Confidence
Indicative
v0.2
Sponsor
GlaxoSmithKline
Modality
Small molecule
Development Phase
Unknown
Status
Dormant
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.

No trial-level evidence is linked to this axis yet.

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Nervous System Cancer

AssetSponsorPhaseRating
Gabapentin (this asset)GlaxoSmithKlineUnkD · 30
CabazitaxelSanofiP1/2CCC
G 207M.D. Anderson Cancer CenterP1CC

Other indications for Gabapentin

IndicationSponsorPhaseRating
Diabetic Neuropathy—P4BBB · 79
Focal Epilepsy—P4BBB · 77
Postherpetic Neuralgia—P4BBB · 75

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Gabapentin in Nervous System Cancer. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/cyclohexaneacetic-acid-1-aminomethyl-nervous-system-cancer

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →